GSK Manufacturing Hits Another Snag With Lamictal Recall
This article was originally published in The Pink Sheet Daily
Executive Summary
Some Lamictal starter kits may contain an inappropriate dose of the anti-epileptic, which could lead to unsafe rapid titration. GSK estimates that 100,000 kits in the supply chain would be subject to the recall.
You may also be interested in...
FDA Seizure Of Paxil CR, Avandamet Follows GSK's Failure To Recall All Lots
GlaxoSmithKline's February recall involving the two drugs did not encompass all affected lots, FDA says in announcing seizure of all doses and lots of the products. The action follows two "Form 483" reports in the last two years for GSK's Cidra, Puerto Rico facility, where the antidepressant and antidiabetic drugs are manufactured.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
‘The Gruber Moment’: How CBER Got The Answers It Wanted On COVID Vaccine Guidance
As US FDA recovers from aducanumab and looks towards an advisory committee on Pfizer’s COVID vaccine, it’s worth reflecting on how Office of Vaccine Research & Review Director Marion Gruber created positive turning points for the agency during a general discussion of vaccine approval standards at the VRBPAC.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: